Cite
MLA Citation
Xia Pu et al.. “226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study.” Open forum infectious diseases, vol. 9, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100174898648.0x000012